Anzeige
Mehr »
Login
Dienstag, 23.04.2024 Börsentäglich über 12.000 News von 689 internationalen Medien
Der KI-Boom ist vorbei! Aber dieser heiße Sektor verspricht, weiter zu wachsen...
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

Aktuelle News von Edison Investment Research

ZeitAktuelle NachrichtenRatingLeser
29.02.Nano Dimension - Share buyback underway251Nano Dimension has provided a business update that highlights a major R&D milestone, a system sale to a defence customer and the start of a $200m share buyback programme. Management is focused on optimising...
► Artikel lesen
29.02.Good Life Plus - Welcome to the Goodlife!94Good Life Plus (GL+) is an early-stage, entertainment-focused, subscription-based prize draw operator. Based in the UK, the business was founded in 2021. The majority of GL+'s members pay a subscription...
► Artikel lesen
29.02.S&U - Impairments drag FY24 PBT, moderation in FY25169In its trading update between December 2023 and January 2024, S&U announced that FY24 PBT will be 10% to 15% below consensus of c £38m. The key reason is lower collection rates in Advantage of 90% (H123:...
► Artikel lesen
29.02.The Law Debenture Corporation - One plus one equals three180FY23 results for The Law Debenture Corporation (LWDB) show this well-proven, rare combination of a UK investment trust and the cash-generative professional services operating business (IPS) continuing...
► Artikel lesen
29.02.Freelancer - Primed for margin expansion192Freelancer's FY23 results marked a key milestone as the group moved to positive operating EBITDA. Profitability was driven by lower opex than we anticipated as gross marketplace volume (GMV) and revenue...
► Artikel lesen
29.02.Actinogen Medical - Pressing forward with Xanamem211Having shown cognitive activity in prior trials, Actinogen began its XanaMIA Phase IIb study of lead candidate Xanamem in patients with cognitive impairment (CI) associated with mild-to-moderate Alzheimer's...
► Artikel lesen
28.02.OSE Immunotherapeutics - Confidence boost with AbbVie partnership442OSE Immunotherapeutics has announced a global licence and collaboration agreement with AbbVie to develop OSE-230, a novel monoclonal antibody, for the treatment of chronic and severe inflammation. The...
► Artikel lesen
27.02.Pan American Silver - FY23 results: Follow the cash flow846Pan American Silver (PAAS) has released its FY23 financial results, which are in line with our estimates at the EBITDA level, an encouraging outcome given the operationally challenging year. While the...
► Artikel lesen
27.02.CLIQ Digital - Steady progress and share buyback announced490CLIQ Digital showed robust revenue and profit growth in FY23 despite a more challenging backdrop. Revenue was below management guidance and Edison estimates, but profits were in line. Margins dipped...
► Artikel lesen
27.02.OSE Immunotherapeutics - Encouraging OSE-279 clinical update182At the 2024 ESMO Targeted Anticancer Therapies Congress, OSE Immunotherapeutics (OSE) presented encouraging interim results from the Phase I/II dose escalation and expansion study for OSE-279, its anti-PD1...
► Artikel lesen
27.02.Immix Biopharma - 2023 recap with a preview of active year ahead251Immix has shared a 12-month recap, capturing key clinical and regulatory events from 2023, setting the stage for an active 2024. Its lead CAR-T asset (NXC-201) is a B-cell maturation antigen (BCMA)...
► Artikel lesen
26.02.Sylvania Platinum - Sluggish PGM prices affect forecasts347Sylvania's Q224 and H124 results were overshadowed by a lower PGM basket price, which resulted in a 10% reduction in revenue. With the delay in the PGM price recovery we expected, we have pared back...
► Artikel lesen
26.02.SATS ASA - Lean and healthy273SATS continues manifestly to deliver on its strategy of premiumisation with currency adjusted membership revenue up 11% in Q423 (15% for the full year) and assurance of 'significant unleashed potential'...
► Artikel lesen
23.02.Georgia Capital - FY23 NAV TR of 20% in sterling terms240Georgia Capital (GCAP) reported a Q423 NAV total return (TR) of 7.7% in Georgian lari (GEL) terms (3.4% in sterling terms), bringing the FY23 NAV TR to a strong 26.5% (20.4% in sterling terms). The...
► Artikel lesen
23.02.Compagnie des Alpes - New peaks385Galvanised by further strong investment-led sales in FY23 (up by 11% like-for-like), which more than absorbed a near-doubling of energy costs, Compagnie des Alpes (CDA) is awash with growth initiatives...
► Artikel lesen
23.02.IRLAB Therapeutics - Positive FDA mesdopetam outlook following EoP2242IRLAB Therapeutics reported positive feedback from its FDA end-of-Phase II (EoP2) meeting earlier in the week for mesdopetam. According to management, the meeting was held in a constructive and engaging...
► Artikel lesen
22.02.1Spatial - Landmark 1Streetworks contract254SPA has announced that following a successful trial, UK Power Networks has signed a contract to deploy 1Streetworks, 1Spatial's traffic plan automation application. This is a landmark win for this key...
► Artikel lesen
22.02.Cereno Scientific - Differentiated approach in CVD with potential219Cereno Scientific is a clinical-stage biotech, developing treatments for cardiovascular diseases (CVDs) using novel approaches. Its focus on disease-modifying therapies and a collaboration with Abbott...
► Artikel lesen
21.02.Vection Technologies - Contract wins underpin strong start to H224284Vection Technologies secured multiple contracts in February, generating total contract value (TCV) of A$5.8m, with management expecting to recognise the associated revenue and cash across H224. Year...
► Artikel lesen
20.02.Basilea Pharmaceutica - From strength to strength369FY23 was another strong year for Basilea, marked by successive guidance beats and meaningful progress in fortifying its product pipeline. Revenues of CHF157.6m were ahead of guidance, driven by c 23%...
► Artikel lesen
20.02.Pan African Resources - A happy valentine209Pan African Resources' (PAF's) H124 results were released on 14 February, with earnings (and headline earnings) within 1.5% of our forecast and normalised headline earnings within 1.2% of our forecast...
► Artikel lesen
20.02.Wilmington - Focus on governance, risk and compliance242With November's purchase of Astutis, January's sale of MiExact and the proposed Healthcare business disposal, Wilmington is now firmly focused on opportunities within the large global governance, risk...
► Artikel lesen
20.02.Recce Pharmaceuticals - Supportive advancements on the pipeline244Recce Pharmaceuticals has announced several positive developments in recent weeks relating to its therapeutic programmes, particularly for lead anti-infective candidate RECCE® 327 (R327). It entered...
► Artikel lesen
20.02.Dentsu Group - Return to organic growth forecast for FY24281Dentsu's FY23 net revenue was a touch above guidance at Q3, with a better-than-expected operating margin reflecting a good Q4 in Japan, further boosted by a short delay in an IT project pushed out to...
► Artikel lesen
20.02.Ultimovacs - Another ODD boosts the off-the-shelf, universal UV1286Ultimovacs has been granted Orphan Drug designation (ODD) from the European Medicines Agency (EMA) for UV1 in mesothelioma, marking another step forward for the clinical development of its lead universal...
► Artikel lesen